Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer.

Autor: Borque-Fernando A; Servicio de Urología, Hospital Universitario Miguel Servet, IIS-Aragón, Zaragoza, Spain. Electronic address: dr.borque@gmail.com., Pérez-Fentes DA; Servicio de Urología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain., Rodrigo-Aliaga M; Servicio de Urología, Hospital General Universitario de Castellón, Castellón, Spain., Puente-Vázquez J; Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, Spain., Gómez-Iturriaga A; Servicio de Oncología Radioterápica, Hospital Universitario Cruces, Biocruces Bizkaia Health Research Insitute, Barakaldo, Bizkaia, Spain., Unda M; Laboratorio Mixto de Investigación Traslacional en Cáncer de Próstata Cic bioGUNE-Basurto, IIS Biobizkaia, Basurto, Bizkaia, Spain., Calleja-Hernández MA; Servicio de Farmacia, Hospital Universitario Virgen Macarena, Sevilla, Spain., Cózar-Olmo JM; Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, Spain., Álvarez-Ossorio JL; Servicio de Urología, Hospital Universitario Puerta del Mar, Cádiz, Spain.
Jazyk: English; Spanish; Castilian
Zdroj: Actas urologicas espanolas [Actas Urol Esp (Engl Ed)] 2024 Dec; Vol. 48 (10), pp. 703-717. Date of Electronic Publication: 2024 Oct 30.
DOI: 10.1016/j.acuroe.2024.10.005
Abstrakt: Triple therapy with docetaxel, androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) has demonstrated survival benefits in patients with metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with high-risk disease. However, once the use of ADT and docetaxel is established, guidelines do not clearly specify which ARPI is most appropriate. In this work, a literature review to identify phase III clinical trials, systematic reviews, meta-analyses, and clinical practice guidelines on triple therapy in mHSPC was carried out. Evidence and recommendations were qualitatively reviewed to provide guidelines on the most suitable ARPI based on patient risk, disease volume, and nature of metastases (synchronous or metachronous). This review aims to update the previously published consensus on the optimal pharmacological treatment for mHSPC and to expose the opinions of hospital pharmacy, urology and medical and radiation oncology experts.
Competing Interests: Declaration of competing interest Ángel Borque-Fernando: Fees for participation in training sessions: Asofarma, Astellas, Astra-Zeneca, Bayer, GP Pharm, HealthMDx, Ipsen, Janssen, Lacer, MSD. Advisory Board meeting fees: Astellas, Astra-Zeneca, Bayer, Janssen, MSD. Support for attending meetings: Astellas, Astra-Zeneca, Bayer, Ipsen, Janssen, Recordati. Miguel Ángel Calleja-Hernandez: Consultancy fees: Bayer, Astellas, Janssen. Fees for participation in training sessions: Janssen, Bayer, Astellas Pharma, MSD, BMS. Support for attending meetings: Astellas, Bayer, MSD, Janssen, BMS. Cózar-Olmo JM: Fees for participation in training sessions: Astellas, Janssen, Bayer, Rovi, Pfizer. Fees for participation in advisory board meetings: Astellas, Janssen, Bayer, Astrazeneca, Pfizer. Alfonso Gómez de Iturriaga-Piña: Fees for participation in training sessions: Janssen; Astellas Pharma; Bayer; AAA / Novartis. Fees for advisory board Meetings: Janssen, Astellas Pharma, Bayer, Elekta. Support for attending Meetings: Janssen, Ipsen, Astellas Pharma. Daniel Adolfo Pérez-Fentes: Consultancy fees, participation in training events or advisory board meetings: Bayer, Astellas Pharma, Janssen. Support for attending meetings: Bayer, Astellas Pharma, Janssen. Javier Puente-Vázquez: Consultancy fees: MSD, Gilead, Janssen, Roche, Ipsen, BMS, Merck. Fees for participation in training sessions: Janssen, Bayer, Astellas Pharma, Astra Zeneca, BMS, MSD, Ipsen. Fees for advisory board meetings: Roche. Support for attending meetings: Gilead, Pfizer, Merck, Janssen, BMS, MSD. Miguel Rodrigo-Aliaga: Consultancy fees: Janssen, Astellas Pharma, Astra Zeneca, Bayer. Fees for participation in training sessions: Janssen, Astellas Pharma, Bayer, Orion Pharma. Fees for advisory board meetings: Janssen, Astellas Pharma, Bayer. Support for attending meetings: Janssen, Astellas Pharma, Orion Pharma, Bayer, Recordati, Ipsen, Pfizer. Miguel Unda-Urzaiz: Fees for participation in training sessions: Janssen, Astellas Pharma, Bayer, Rovi, Orion Pharma. Fees for advisory board meetings: Janssen, Astellas Pharma, Bayer. Support for attending meetings: Janssen, Astellas Pharma, Orion Pharma, Bayer, Recordati, Rovi, Ipsen, Pfizer. José L Álvarez-Ossorio: Fees for participation in training sessions: Astellas, Janssen, Bayer, Rovi, Pfizer. Fees for participation in advisory board meetings: Astellas, Janssen, Bayer, AstraZeneca, Pfizer.
(Copyright © 2024 AEU. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: